U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-16-1073
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Food and Drug Administration Drug Approval Summary: Sunitinib Malate for the Treatment of Gastrointestinal Stromal Tumor and Advanced Renal Cell Carcinoma

Oncologist
Cancer ResearchMedicineOncology
2007English

U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients With Intermediate and High-Risk Myelofibrosis

Clinical Cancer Research
Cancer ResearchOncology
2012English

Spotlight on Cabozantinib for Previously Untreated Advanced Renal Cell Carcinoma: Evidence to Date

Cancer Management and Research
Oncology
2018English

Cabozantinib in Combination With Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Nivolumab in the Treatment of Advanced Renal Cell Carcinoma

Oncology in Clinical Practice
Oncology
2019English

Transparency and Dermatologic Device Approval by the US Food and Drug Administration

JAMA Dermatology
DermatologyMedicine
2018English

U.S. Food and Drug Administration Approval: Panitumumab for Epidermal Growth Factor Receptor-Expressing Metastatic Colorectal Carcinoma With Progression Following Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Containing Chemotherapy Regimens

Clinical Cancer Research
Cancer ResearchOncology
2008English

Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma in Adults Following Prior Vascular Endothelial Growth Factor Targeted Therapy: Clinical Trial Evidence and Experience

Therapeutic Advances in Urology
Urology
2018English

Practical Management of Adverse Events Associated With Cabozantinib Treatment in Patients With Renal-Cell Carcinoma

OncoTargets and Therapy
OncologyPharmacology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy